Release date: 2007-11-05
Recent advancements in the study of collateral diseases in China have gained significant attention on the global stage. At the 3rd International Conference on Collateral Diseases, Professor Wu Yiling, a leading scientist from the National 973 Program, delivered an influential lecture on the foundational theories of vascular disease guided by the concept of collateral diseases. His presentation attracted wide interest from experts and scholars across the country, as well as from the United States and South Korea. Over 800 participants from India and other nations engaged with his work, offering positive feedback and recognition. This marks another major breakthrough in the field of collateral research, following the National Science and Technology Progress Second Prize that Professor Wu received earlier this year.
Collateral diseases represent a complex pathological condition commonly found in chronic and refractory conditions such as cardiovascular diseases, cerebrovascular diseases, and diabetic vascular complications. It has become a key area of focus in national basic medical research. Currently, more than 20 universities in China, including Peking University, Zhongshan University, and Xiamen University, have incorporated collateral disease education into their curricula. Additionally, Harvard Medical School includes the study of collateral diseases as part of its continuing medical education for physicians.
Professor Wu Yiling has dedicated over two decades to exploring the theoretical framework of collateral diseases. He introduced the "three-dimensional network system" model, significantly advancing the application of collateral disease theory in the prevention and treatment of vascular lesions. His work has led to the development of several effective traditional Chinese medicine treatments, such as Tongxinluo Capsule for coronary heart disease, Shensong Yangxin Capsule for arrhythmia, and Qiqiangxin Capsule for chronic heart failure. These innovations have formed a new generation of drugs in the treatment of cardiovascular and cerebrovascular diseases. Notably, "Tongxinluo Capsule for the Treatment of Coronary Heart Disease" was awarded the Second Prize of the National Science and Technology Progress Award.
Today, the research and clinical evaluation of Tongxinluo-based therapies are being widely conducted throughout China. According to preliminary statistics, over 1,000 scientific papers on Tongxinluo have been published in biomedical journals worldwide. These studies reflect the extensive experimental and clinical validation of the collateral disease theory, enriching the scientific foundation of traditional Chinese medicine and highlighting its modern relevance.
— China Medicine 123 Network
Stainless Steel Cleanroom Furniture
Stainless Steel Furniture,Stainless Steel Cleanroom Furniture,Cleanroom Furniture
AUSTAR Goup , https://www.hansencleanroom.com